Minocyclinum [Inn-Latin] en es it fr

Minocyclinum [Inn-Latin] Brand names, Minocyclinum [Inn-Latin] Analogs

Minocyclinum [Inn-Latin] Brand Names Mixture

  • No information avaliable

Minocyclinum [Inn-Latin] Chemical_Formula


Minocyclinum [Inn-Latin] RX_link


Minocyclinum [Inn-Latin] fda sheet

Minocyclinum_[Inn-Latin] FDA

Minocyclinum [Inn-Latin] msds (material safety sheet)

Minocyclinum_[Inn-Latin] MSDS

Minocyclinum [Inn-Latin] Synthesis Reference

Boothe, Petisi, U.S. Pat. 3,148,212 (1964)

Minocyclinum [Inn-Latin] Molecular Weight

457.477 g/mol

Minocyclinum [Inn-Latin] Melting Point

No information avaliable

Minocyclinum [Inn-Latin] H2O Solubility

52 mg/mL

Minocyclinum [Inn-Latin] State


Minocyclinum [Inn-Latin] LogP


Minocyclinum [Inn-Latin] Dosage Forms

Capsules; Subgingival (sustained-release); IV injection

Minocyclinum [Inn-Latin] Indication

For the treatment of infections caused by susceptible strains of microorganisms, such as Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsial pox and tick fevers caused by Rickettsiae, upper respiratory tract infections caused by Streptococcus pneumoniae and for the treatment of asymptomatic carriers of Neisseria meningitidis.

Minocyclinum [Inn-Latin] Pharmacology

Minocycline, the most lipid soluble and most active tetracycline antibiotic, is, like doxycycline, a long-acting tetracycline. Minocycline's effects are related to the inhibition of protein synthesis. Although minocycline's broader spectrum of activity, compared to other members of the group, includes activity against Neisseria meningitidis, its use as a prophylaxis is no longer recomended because of side effects (dizziness and vertigo). Current research is examining the possible neuroprotective effects of minocycline against progression of Huntington's Disease, an inherited neurodegenerative disorder. The neuroprotective action of minocycline may include its inhibitory effect on 5-lipoxygenase, an inflammatory enzyme associated with brain aging.

Minocyclinum [Inn-Latin] Absorption

Rapidly absorbed from the gastrointestinal tract and absorption is not significantly impaired by ingestion of food or milk. Oral bioavailability is 100%.

Minocyclinum [Inn-Latin] side effects and Toxicity

Minocycline has been observed to cause a dark discoloration of the thyroid in experimental animals (rats, minipigs, dogs and monkeys). In the rat, chronic treatment with minocycline has resulted in goiter accompanied by elevated radioactive iodine uptake and evidence of thyroid tumor production. Minocycline has also been found to produce thyroid hyperplasia in rats and dogs. LD50=2380 mg/kg (rat, oral), LD50=3600 mg/kg (mouse, oral)

Minocyclinum [Inn-Latin] Patient Information

Minocyclinum [Inn-Latin] Organisms Affected

Enteric bacteria and other eubacteria